Article
Endocrinology & Metabolism
Laura J. Reid, Fraser W. Gibb, Helen Colhoun, Sarah H. Wild, Mark W. J. Strachan, Karen Madill, Baljean Dhillon, Shareen Forbes
Summary: This study compared the progression of diabetic retinopathy in patients with type 1 diabetes who received CSII therapy versus MDI therapy. The results showed that CSII therapy was associated with reduced progression of diabetic retinopathy compared to continued MDI therapy, especially for patients with high baseline HbA(1c). The progression of retinopathy over 3 years was not affected by changes in HbA(1c).
Article
Endocrinology & Metabolism
Xu Wang, Xue Zhao, Danrong Chen, Mingzhi Zhang, Wei Gu
Summary: A comparison of treatment regimens for T1D in children using a combination of meta-analysis and prospective cohort study revealed that CSII may be associated with better glycemic control and growth development without increasing the risk of long-term complications or delaying puberty.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Review
Medicine, General & Internal
Vasiliki Chatziravdeli, George I. I. Lambrou, Athanasia Samartzi, Nikolaos Kotsalas, Eugenia Vlachou, John Komninos, Athanasios N. N. Tsartsalis
Summary: Diabetes mellitus (DM) is becoming more prevalent worldwide, even in developing countries. While there are many antidiabetic agents available, insulin is often necessary for patients with inadequate glycemic control. However, the optimal timing for insulin administration is still a topic of research. This meta-analysis examined the use of continuous subcutaneous insulin infusion (CSII) in patients with Type 2 Diabetes Mellitus (T2DM) and found that CSII may be beneficial in helping patients achieve their glycemic targets.
MEDICINA-LITHUANIA
(2023)
Article
Endocrinology & Metabolism
Tugba Barlas, Mehmet Muhittin Yalcin, Meric Coskun, Dilek Demirel, Alev Eroglu Altinova, Fusun Balos Toruner, Mehmet Ayhan Karakoc, Ilhan Yetkin, Mujde Akturk
Summary: The objective of this study was to determine lipohypertrophy (LH) in patients with type 1 diabetes mellitus on multiple daily insulin injections (MDII) or continuous subcutaneous insulin infusion (CSII) and to identify factors associated with LH development and severity. LH localizations were detected using palpation and ultrasonography (USG), with USG showing a significantly higher detection rate in the whole group. LH was more severe in the MDII group than in the CSII group, and its severity was positively correlated with HbA1C and insulin dose. MDII as an insulin administration method, incorrect rotation technique, and a history of ketosis were found to be the most related factors with LH severity.
ENDOCRINE PRACTICE
(2023)
Article
Public, Environmental & Occupational Health
Keyu Guo, Jiaqi Li, Liyin Zhang, Jianan Ye, Li Fan, Zhiyi Ding, Qin Zhou, Xia Li, Lin Yang, Zhiguang Zhou
Summary: This study compared the efficacy of continuous subcutaneous insulin infusion (CSII) therapy with multiple daily injection (MDI) therapy in Chinese patients with type 1 diabetes mellitus (T1DM). The results showed that CSII therapy was associated with lower HbA1c levels and better glycemic outcomes. However, it did not improve the risk of hypoglycemia.
FRONTIERS IN PUBLIC HEALTH
(2022)
Article
Endocrinology & Metabolism
Mark Warren, Bruce Bode, Jang I. Cho, Rong Liu, Janet Tobian, Thomas Hardy, Farai Chigutsa, Moshe Phillip, Barry Horowitz, Debra Ignaut
Summary: The study found that in patients with type 1 diabetes using CSII, URLi was more effective in improving postprandial glucose control and reducing time spent in hypoglycemia compared to lispro.
DIABETES OBESITY & METABOLISM
(2021)
Review
Endocrinology & Metabolism
Carlos A. Diaz-Balzac, David Pillinger, Steven D. Wittlin
Summary: Continuous subcutaneous insulin infusions (CSIIs) and continuous glucose monitors (CGMs) have revolutionized the management of diabetes mellitus (DM). They provide an integrated system to maintain tight glycemic control and reduce episodes of hypoglycemia, while improving the quality of life for individuals with DM. Ongoing efforts to develop an artificial pancreas (AP) have created effective tools for managing DM, but cost and accessibility remain obstacles to wider application.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Monika Zurawska-Klis, Marcin Kosinski, Andzelika Kuchnicka, Milena Rurka, Judyta Halucha, Marzena Wojcik, Katarzyna Cypryk
Summary: This study compared the pregnancy outcomes, glycemic control, insulin requirement, and weight gain in pregnant women with Type 1 Diabetes Mellitus using continuous subcutaneous insulin infusion or multiple daily injections. The results showed that pregnancy and obstetric outcomes were not dependent on the mode of insulin delivery, but rather on pregnancy planning and HbA1c levels in early pregnancy.
DIABETES RESEARCH AND CLINICAL PRACTICE
(2021)
Article
Endocrinology & Metabolism
Caterina Policola, Enrico Di Stasio, Alessandro Rizzi, Francesca Foca, Linda Tartaglione, Pietro Locantore, Vittoria Ramunno, Maria Laura Leo, Daniela Pia Rosaria Chieffo, Lucio Rinaldi, Silvia Della Casa, Alfredo Pontecorvi, Dario Pitocco
Summary: This study aims to evaluate predisposition to eating disorders and body dissatisfaction in adults with type 1 diabetes mellitus (T1DM) and investigate any differences in ED predisposition between subjects with T1DM on multiple daily injections (MDI) or insulin pumps (CSII) and healthy control subjects.
DIABETES RESEARCH AND CLINICAL PRACTICE
(2023)
Article
Endocrinology & Metabolism
David Rodbard, Satish K. Garg
Summary: This study proposes a prototype for a standardized method for data analysis and display for patients on MDI using connected pens and CGM, aiming to provide a consistent format for glucose, insulin, meals, and activity data.
DIABETES TECHNOLOGY & THERAPEUTICS
(2021)
Article
Engineering, Biomedical
Shereen Kesserwan, Adam Mulka, Roshanak Sharafieh, Yi Qiao, Rong Wu, Donald L. Kreutzer, Ulrike Klueh
Summary: The presence of phenolic compounds in commercial insulin preparations may be toxic to cells and tissues, contributing to the failure of effective insulin infusion therapy.
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
(2021)
Article
Psychology, Clinical
Ella Dowling, David W. Maidment
Summary: This study finds that adults with type 1 diabetes using multiple daily injections (MDI) insulin delivery method have lower scores on measures of depressive symptoms and diabetes distress compared to those using continuous subcutaneous insulin infusion (CSII). MDI users may require more targeted support to improve their psychological well-being.
JOURNAL OF HEALTH PSYCHOLOGY
(2023)
Article
Endocrinology & Metabolism
Jieling Chen, Ludi Fan, Xiaomei Peng, Liza Ilag, Trang Ly, Jennal Johnson
Summary: The study revealed that individuals with type 2 diabetes receiving treatment with U-500R insulin reported improvements in diabetes management, treatment burden, and psychological health, with greater improvements seen in the CSII group. Both the CSII and MDI methods were similarly acceptable in terms of delivery device and function.
DIABETES OBESITY & METABOLISM
(2021)
Article
Endocrinology & Metabolism
Ralph Ziegler, Nick Oliver, Delia Waldenmaier, Jochen Mende, Cornelia Haug, Guido Freckmann
Summary: The evaluation revealed significant differences between the tested tubeless pump models, with ACS being more accurate than A6 and A6 less accurate than OP. These differences were most evident in terms of delivery errors over short times and small volumes.
DIABETES TECHNOLOGY & THERAPEUTICS
(2021)
Article
Medicine, General & Internal
Lijuan Zhang, Xuefei Leng, Fei Tian, Dunming Xiao, Jianwei Xuan, Hongxiu Yang, Jing Liu, Zhihong Chen
Summary: In Qingdao, China, continuous subcutaneous insulin infusion (CSII) therapy has been found to be more cost-effective than multiple daily injections (MDI) therapy for children and adolescent patients with type 1 diabetes (T1D). It should be considered as the preferred treatment modality.
POSTGRADUATE MEDICINE
(2022)